心通医疗(02160.HK)产品VitaFlow Liberty Flex获国家药监局批准注册

阿斯达克财经2024-12-18

心通医疗－Ｂ(02160.HK) 公布，集团自主研发的第三代经导管主动脉瓣植入术（TAVI）产品VitaFlow Liberty Flex经导管主动脉瓣可回收可控弯输送系统获中国国家药品监督管理局颁发注册批准。VitaFlow LibertyFlex为VitaFlow Liberty输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2492994792?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220906143939119_s.jpg","is_english":false,"pubTime":"2024-12-18 03:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492994792","market":"other","top_or_hot":-1,"title":"心通医疗(02160.HK)产品VitaFlow Liberty Flex获国家药监局批准注册","media":"阿斯达克财经","content":"<div>\n<p>心通医疗－Ｂ(02160.HK) 公布，集团自主研发的第三代经导管主动脉瓣植入术（TAVI）产品VitaFlow Liberty Flex经导管主动脉瓣可回收可控弯输送系统获中国国家药品监督管理局颁发注册批准。VitaFlow LibertyFlex为VitaFlow Liberty输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404787/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心通医疗(02160.HK)产品VitaFlow Liberty Flex获国家药监局批准注册</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心通医疗(02160.HK)产品VitaFlow Liberty Flex获国家药监局批准注册\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 03:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404787/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>心通医疗－Ｂ(02160.HK) 公布，集团自主研发的第三代经导管主动脉瓣植入术（TAVI）产品VitaFlow Liberty Flex经导管主动脉瓣可回收可控弯输送系统获中国国家药品监督管理局颁发注册批准。VitaFlow LibertyFlex为VitaFlow Liberty输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404787/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02160","symbol_name":"心通医疗-B","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404787/latest-news/AAFN","article_id":"2492994792","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220906143939119_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492994792","pubTimestamp":1734464640,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"心通医疗－Ｂ(02160.HK) 公布，集团自主研发的第三代经导管主动脉瓣植入术（TAVI）产品VitaFlow Liberty Flex经导管主动脉瓣可回收可控弯输送系统获中国国家药品监督管理局颁发注册批准。VitaFlow LibertyFlex为VitaFlow Liberty输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02160":"心通医疗-B","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1100":"医疗保健设备"},"translate_title":"Xintong Medical (02160. HK) product VitaFlow Liberty Flex was approved for registration by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1},"content_text":"心通医疗－Ｂ(02160.HK) 公布，集团自主研发的第三代经导管主动脉瓣植入术（TAVI）产品VitaFlow Liberty Flex经导管主动脉瓣可回收可控弯输送系统获中国国家药品监督管理局颁发注册批准。VitaFlow LibertyFlex为VitaFlow Liberty输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492994792"}